DocDollars

Fujirebio Diagnostics, Incorporated

PA · United States · Reporting entity ID 100000010917

Total reported 2019–2025
$16.1M
#368 of 2,960 reporting companies — 0% of all reported industry payments
$15.1M in general payments across 98 records, plus $990K in research funding across 43 records.

How it breaks down

General payments $15,094,503
Research funding $990,290

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Fujirebio Diagnostics, Incorporated reported $16.1M to US doctors and teaching hospitals from 2019 to 2025, ranking #368 of 2,960 reporting companies. 6% of that was research funding and 94% general payments such as consulting, speaking, food and travel. 98 general payment records and 43 research records were filed.

Common questions about Fujirebio Diagnostics, Incorporated

How much has Fujirebio Diagnostics, Incorporated paid US doctors?

Fujirebio Diagnostics, Incorporated reported $16,084,793 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $15,094,503 in general payments, $990,290 in research funding.

How does Fujirebio Diagnostics, Incorporated rank among drug and device companies?

It ranks #368 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Fujirebio Diagnostics, Incorporated mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.